SCHEMBL29327895

SCHEMBL29327895

CCc1ccc(-c2nc3cc(NC(=O)c4cc(C#N)ccc4S(C)(=O)=O)cc(Cl)c3o2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 6/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ CYP2C8 P10632 2/20 0.45
▸ MAPT P10636 5/20 0.44
▸ TP53 P04637 4/20 0.44
▸ CETP P11597 4/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ POLB P06746 1/20 0.41
▸ THRB P10828 1/20 0.40
▸ CEPT1 Q9Y6K0 1/20 0.40
▸ NR1I2 O75469 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327936 0.92 PPARG (0.60) PPARGSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL29327893 0.90 PPARG (0.57) PPARGSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL29327984 0.87 PPARG (0.52) PPARGSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL29328005 0.87 PPARG (0.58) PPARGSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL29327587 0.86 PPARG (0.77) PPARGSMN1; SMN2CYP2C8MAPTTP53
SCHEMBL29327959 0.85 PPARG (0.49) PPARGSMN1; SMN2CYP2C8MAPTTP53
SCHEMBL29327605 0.84 PPARG (0.67) PPARGSMN1; SMN2CYP2C8MAPTTP53
SCHEMBL29327933 0.83 PPARG (0.55) PPARGSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL29327683 0.78 PPARG (0.72) PPARGSMN1; SMN2CYP2C8MAPTTP53
SCHEMBL27188286 0.78 PPARG (1.00) PPARGSMN1; SMN2CYP2C8MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885SMN1; SMN2 3738/4885KDM4E 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback